



In Search of Excellence

ORION PHARMA LIMITED

Registered Office: Orion House, 153-154 Tejgaon I/ A, Dhaka

UN-AUDITED HALF YEARLY (Q2) FINANCIAL STATEMENTS

This is to inform you all concerned that the un-audited condensed consolidated financial statements of Orion Pharma Limited as on and for the Half Yearly (Q2) period ended on December 31, 2023 has been adopted by the Board of Directors in its meeting held on January 31, 2024 at 4:00 pm in the registered office at Orion House, 153-154 Tejgaon I/ A, Dhaka-1208. The excerpts of the Financial Statements are as follows:

Particulars		December 31, 2023	December 31, 2022	Oct to Dec 2023	Oct to Dec 2022
Consolidated Earnings Per Share (EPS) - Q2	:	BDT 1.23	BDT 1.91	BDT 0.47	BDT 1.19
Consolidated Net Operating Cash Flow Per Share (NOCFPS) - Q2	:	BDT 2.68	BDT 5.62	--	--
		December 31, 2023		June 30, 2023	
Consolidated Net Asset Value (NAV) Per Share - Q2 (Including Revaluation Surplus)	:	BDT 89.69		BDT 88.99	
Consolidated Net Asset Value (NAV) Per Share - Q2 (Excluding Revaluation Surplus)	:	BDT 81.87		BDT 81.15	

The detailed Financial Statements are also available in the Company's website: www.orionpharma.com

Sd/-

Md. Ferdous Jaman

Company Secretary

Date: January 31, 2024